Equashield Penetrates Five New Markets with Exclusive Distributor Partnerships

PORT WASHINGTON, New York, July 13, 2016 /PRNewswire/ --

Leading Closed System Transfer Device Vendor Partners with Top French, Swiss, Spanish, Thai and Polish Medical Device Sellers  

Equashield, a leading provider of Closed System Transfer Devices (CSTDs) for safe and simple handling of hazardous drugs, today announced that it has signed five international partnerships with distributers in France, Switzerland, Spain, Poland and Thailand.

Equashield has now significantly increased its presence in Europe, with new agreements in place with Macopharma in France, Aegis Medical Technologies GMBH in Switzerland, Palex Medical SA in Spain, and Poland's Laboclinic. Equashield also continues to extend its presence in Southeast Asia through its partnership with Advance Medical Life in Thailand.

"These partnerships illustrate the industry's confidence in Equashield as a strong partner for medical facilities who are continuously striving to provide the safest products possible to healthcare workers handling hazardous substances," said Marino Kriheli, Co-founder of Equashield. "We expect to see more distributers join us to continue this momentum and make a difference for those who work with and around hazardous drugs. Equashield's is the only truly closed system that provides protection from multiple routes of exposure."

The arrival of EQUASHIELD® to these new markets builds on last year's rapid growth for the company, which reported a 160% increase in sales with over twenty countries using EQUASHIELD® internationally.

"Equashield is quickly becoming the CSTD of choice for protecting healthcare professionals across the globe. Our significant growth is evidence of increasing confidence in Equashield's ability to protect against more routes of exposure than alternative devices," added Kriheli.

About Equashield 

Equashield is a leading provider of Closed System Transfer Devices (CSTDs), clinically proven to protect healthcare professionals from hazardous drug exposure. Incorporating a pioneering design, the company's flagship device, EQUASHIELD^® II, covers more routes of exposure than alternative systems by preventing: contamination of syringe plungers, drug residuals on connector surfaces as well as exposure to drug vapor. Studies have shown Equashield's CSTD to be faster to deploy and easier to use than competing systems and has passed NIOSH's proposed vapor containment protocol, confirming that it can contain vapors/emissions within the limits of the proposed testing. The EQUASHIELD system has been cleared by the FDA under the ONB product code and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days. 

For more information: http://www.equashield.com

Media Contact:
Finn Partners for Equashield
Glenn Jasper
goel.jasper@finnpartners.com
@goeljasper
+1-929-222-8002